Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLAG: LITT for Newly Diagnosed Glioblastoma
NCT02880410Phase 1Terminated
- Sponsor
- Monteris Medical
- Start
- Aug 2017
- Primary completion
- Sep 2018
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial, sponsored by Monteris Medical. Primary endpoint: Adverse Events at 2 years. Started Aug 2017; status: terminated.
Beyond the preview
Go deeper on NCT02880410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02880410.